[Allogeneic hematopoietic stem cell transplantations]

Area of Science:

• Immunotherapy
• Onco-hematology
• Transplantation immunology

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is a primary immunotherapy leveraging graft immune effectors against patient tumor cells.
• Its efficacy relies on conditioning regimens and graft-versus-tumor (GVL/GVT) effects.
• Current research focuses on refining HSCT for better patient outcomes.

Purpose of the Study:

• To review the evolving landscape of allogeneic HSCT.
• To highlight advancements in understanding GVT mechanisms.
• To discuss new therapeutic strategies and their integration into onco-hematology.

Main Methods:

• Review of current allogeneic HSCT techniques and mechanisms.
• Analysis of advancements in donor selection and conditioning regimens.
• Discussion of immunomodulatory strategies like donor lymphocyte infusion (DLI).

Main Results:

• Allogeneic HSCT is undergoing significant evolution due to improved GVT understanding.
• New techniques include peripheral blood stem cells, cord blood, unrelated/haplo-identical donors, and reduced-intensity conditioning.
• Immunomodulation and sequential therapies are enhancing treatment efficacy.

Conclusions:

• Allogeneic HSCT, a potent immunotherapy, requires strategic refinement.
• It offers significant benefits for specific patient subgroups in onco-hematology.
• Integration into global therapeutic strategies is crucial for maximizing its potential.